Introduction to Choosing Cancer Clinical Trial Endpoints
Let's dive into the details surrounding Choosing Cancer Clinical Trial Endpoints. Bruce Burnett, Swansea University, Swansea, UK, highlights the important considerations when
Choosing Cancer Clinical Trial Endpoints Comprehensive Overview
Dr. Loriot (FR) gives a lecture on " Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ... The FDA
Researchers in the NCI Community
Summary & Highlights for Choosing Cancer Clinical Trial Endpoints
- Sara Tolaney, MD, MPH discuses updated standardized definitions for efficacy
- Presentation Title: Use of Surrogate
- Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast
- Carol Aghajanian, MD, from the Memorial Sloan-Kettering
- Elihu H. Estey, MD, from the Seattle
That wraps up our extensive overview of Choosing Cancer Clinical Trial Endpoints.
